awmsg logo



glycopyrronium bromide (Seebri Breezhaler®)


Reference No. 1455

Publication date:
22/05/2013


Appraisal information

glycopyrronium bromide (Seebri Breezhaler®) 44 micrograms inhalation powder


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Respiratory system
NMG meeting date: 20/02/2013
AWMSG meeting date: 20/03/2013
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0713
Ministerial ratification: 22/05/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Glycopyrronium bromide (Seebri® Breezhaler®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download